U.S. Markets closed

Galena price target raised to $9 from $6 at Maxim

Maxim raised its price target for Galena shares to $9 citing increased confidence in the development pipeline after the company said it started enrollment of a phase II trial for its second anti-cancer agent GALE-301. The firm reiterates a Buy rating on the stock.